Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021

URL

https://jamanetwork.com/journals/jama/fullarticle/2788346

Authors

Matthew E. Oster, David K. Shay, John R. Su, Julianne Gee, C. Buddy Creech, Karen R. Broder, Kathryn Edwards, Jonathan H. Soslow, Jeffrey M. Dendy, Elizabeth Schlaudecker, Sean M. Lang, Elizabeth D. Barnett, Frederick L. Ruberg, Michael J. Smith, M. Jay Campbell, Renato D. Lopes, Laurence S. Sperling, Jane A. Baumblatt, Deborah L. Thompson, Paige L. Marquez, Penelope Strid, Jared Woo, River Pugsley, Sarah Reagan-Steiner, Frank DeStefano, and Tom T. Shimabukuro

Published Date

January 25, 2022

Publication

JAMA (Journal of the American Medical Association)

Organization

CDC (Centers for Disease Control & Prevention)

Additional Information

Funding/Support: This work was supported by contracts 200-2012-53709 (Boston Medical Center), 200-2012-53661 (Cincinnati Children’s Hospital Medical Center), 200-2012-53663 (Duke University), and 200-2012-50430 (Vanderbilt University Medical Center) with the US Centers for Disease Control and Prevention (CDC) Clinical Immunization Safety Assessment Project.

Medium

document

Topics

adverse events,COVID-19,heart disorders,mRNA,vaccines